A novel combination therapy today received the greenlight to proceed with testing from regulators in Nepal. The project resulted from a collaboration between Sen-Jam Pharmaceutical Partners, Duke-NUS in Singapore and Duke University School of Medicine. The partnership was first announced in August 2021.
The phase II study will test the efficacy of an oral combination therapy that joins an antihistamine with a non-steroidal anti-inflammatory drug to mitigate severe symptoms and hospitalisation due to COVID-19. The researchers — including Associate Professor Ashley St John from Duke-NUS and Professor Alexander Limkakeng from Duke — believe that in combination the two will disrupt the body’s inflammatory process.